vs
Aspire Biopharma Holdings, Inc.（ASBP）与ORAMED PHARMACEUTICALS INC.（ORMP）财务数据对比。点击上方公司名可切换其他公司
Aspire Biopharma Holdings, Inc.是一家临床阶段生物制药公司，专注开发肿瘤及罕见病领域的创新候选疗法，满足未被覆盖的医疗需求，业务主要分布于北美及亚太重点市场。
Oramed制药公司成立于2006年，总部位于耶路撒冷，专注于开发口服给药系统，核心产品为用于治疗2型糖尿病的口服胰岛素胶囊，是一家公开上市企业，股票同时在纳斯达克资本市场和特拉维夫证券交易所挂牌交易。
ASBP vs ORMP — 直观对比
营收规模更大
ASBP
是对方的Infinity倍
$0
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.9K | $0 |
| 净利润 | $-1.9M | $10.0M |
| 毛利率 | 45.5% | — |
| 营业利润率 | -59015.8% | — |
| 净利率 | -95337.1% | — |
| 营收同比 | — | — |
| 净利润同比 | -755.6% | 198.2% |
| 每股收益（稀释后） | $-0.04 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASBPORMP
| Q4 25 | — | $0 | ||
| Q3 25 | $1.9K | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $2.0M | ||
| Q4 23 | — | $0 | ||
| Q3 23 | — | $0 | ||
| Q2 23 | — | $674.0K | ||
| Q1 23 | — | $666.0K |
净利润ASBPORMP
| Q4 25 | — | $10.0M | ||
| Q3 25 | $-1.9M | $48.4M | ||
| Q2 25 | — | $13.3M | ||
| Q1 25 | — | $-7.6M | ||
| Q4 23 | — | $12.9M | ||
| Q3 23 | — | $-3.2M | ||
| Q2 23 | — | $-1.2M | ||
| Q1 23 | — | $-3.4M |
毛利率ASBPORMP
| Q4 25 | — | — | ||
| Q3 25 | 45.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.7% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
营业利润率ASBPORMP
| Q4 25 | — | — | ||
| Q3 25 | -59015.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -225.0% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -562.5% | ||
| Q1 23 | — | -782.0% |
净利率ASBPORMP
| Q4 25 | — | — | ||
| Q3 25 | -95337.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -382.1% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -177.2% | ||
| Q1 23 | — | -509.8% |
每股收益（稀释后）ASBPORMP
| Q4 25 | — | $0.25 | ||
| Q3 25 | $-0.04 | $1.13 | ||
| Q2 25 | — | $0.31 | ||
| Q1 25 | — | $-0.19 | ||
| Q4 23 | — | $0.33 | ||
| Q3 23 | — | $-0.08 | ||
| Q2 23 | — | $-0.03 | ||
| Q1 23 | — | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $51.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-11.5M | $199.7M |
| 总资产 | $2.4M | $230.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASBPORMP
| Q4 25 | — | $51.4M | ||
| Q3 25 | — | $57.1M | ||
| Q2 25 | — | $17.6M | ||
| Q1 25 | — | $3.7M | ||
| Q4 23 | — | $66.8M | ||
| Q3 23 | — | $49.4K | ||
| Q2 23 | — | $943.0K | ||
| Q1 23 | — | $2.3M |
总债务ASBPORMP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $74.5M | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
股东权益ASBPORMP
| Q4 25 | — | $199.7M | ||
| Q3 25 | $-11.5M | $203.3M | ||
| Q2 25 | — | $154.5M | ||
| Q1 25 | — | $140.8M | ||
| Q4 23 | — | $163.8M | ||
| Q3 23 | — | $149.1M | ||
| Q2 23 | — | $151.5M | ||
| Q1 23 | — | $151.0M |
总资产ASBPORMP
| Q4 25 | — | $230.9M | ||
| Q3 25 | $2.4M | $220.5M | ||
| Q2 25 | — | $161.7M | ||
| Q1 25 | — | $147.5M | ||
| Q4 23 | — | $220.6M | ||
| Q3 23 | — | $230.9M | ||
| Q2 23 | — | $156.3M | ||
| Q1 23 | — | $159.8M |
负债/权益比ASBPORMP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | 0.50× | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.1M | $-466.0K |
| 自由现金流经营现金流 - 资本支出 | — | $-468.0K |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | -0.05× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASBPORMP
| Q4 25 | — | $-466.0K | ||
| Q3 25 | $-1.1M | $-1.6M | ||
| Q2 25 | — | $-3.5M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 23 | — | $-1.4M | ||
| Q3 23 | — | $-694.0K | ||
| Q2 23 | — | $-2.6M | ||
| Q1 23 | — | $-5.5M |
自由现金流ASBPORMP
| Q4 25 | — | $-468.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-3.5M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 23 | — | $-1.4M | ||
| Q3 23 | — | $-726.0K | ||
| Q2 23 | — | $-2.7M | ||
| Q1 23 | — | $-5.7M |
自由现金流率ASBPORMP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -176.1% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -393.8% | ||
| Q1 23 | — | -863.1% |
资本支出强度ASBPORMP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.1% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 3.0% | ||
| Q1 23 | — | 29.9% |
现金转化率ASBPORMP
| Q4 25 | — | -0.05× | ||
| Q3 25 | — | -0.03× | ||
| Q2 25 | — | -0.27× | ||
| Q1 25 | — | — | ||
| Q4 23 | — | -0.11× | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
